Source disclosure: January 14, 2026
H.U. Group Holdings,Inc. [4544.T]
TOKYO, Jan 14 (Pulse News Wire) – H.u. Group Holdings,inc.
Ishikawa previously served as executive vice president and concurrently held the position of group CEO. He succeeds Takeuchi Shigeazu, who will transition to a role as a director and executive officer. Ishikawa's appointment follows the company’s mid-term management plan “H.U. 2030,” which was introduced in May 2025 along with a CEO succession plan aimed at achieving the desired state by 2035.
His extensive contributions to the growth of the clinical diagnostic reagents (IVD) division since joining the company in 2012 made him the ideal candidate to lead the company’s strategic initiatives and execution moving forward. Born on November 18, 1976, Ishikawa holds 20.1 thousand shares of the company stock as of June 2025. Prior to his tenure at H.U. Group Holdings, he worked at the Defense Agency (now Ministry of Defense), Harvard Business School, Boston Consulting Group, Elsevier, and Fujirebio, among others. Ishikawa currently serves as a director at Fujirebio Diagnostics Inc., Fujirebio Europe NV, Fuji Film Holdings Corporation, and SR Holdings Corporation.
AI-translated content. 🟢 Confidence: High See terms • Original filing